Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper reviews existing and emerging therapies for alopecia areata, describing the impact of targeted treatments in this field, and introduces a global network of disease registers to study the long-term safety and effectiveness of these new options.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

This study found that both a nutritional supplement and a topical hair lotion reduced hair loss and increased the anagen to telogen hair ratio in individuals with androgenetic alopecia.

This study found that online materials about alopecia areata and its treatments are generally difficult to understand, with information on JAK inhibitors being particularly challenging, highlighting a need for clearer educational resources for patients.

This study found that cortexolone 17α-propionate (clascoterone) effectively inhibited androgen receptor-regulated transcription and IL-6 synthesis in scalp cells, potentially making it a promising candidate for topical treatment of androgenetic alopecia.

This study observed that a combination of two mineral and nutritional supplement products increased anagen-phase hair and reduced hair loss in women with androgenetic alopecia and acute or chronic telogen effluvium after four months.

This study found that topical application of Serenoa repens extract increased hair count in men with androgenetic alopecia, suggesting it could be an alternative for those unable to use standard medications.

This study found that suppressing allopregnanolone production in late gestation fetal sheep altered CNS activity and behavioral responses to transient asphyxia, effects mitigated by an analog co-infusion.

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This Cochrane review reports that 5-alpha reductase inhibitors may slightly reduce urological symptoms and acute urinary retention risk compared to placebo, with a possible small reduction in surgical intervention need compared to alpha blockers.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This study found significant structural and compositional differences in hair affected by alopecia areata compared to healthy hair, using a range of physico-chemical investigation methods.

This systematic review identified topical and oral minoxidil as the most effective treatments for monilethrix, but noted the varying efficacy of oral retinoids and other treatments.

This case report describes an 8-year-old boy with acrodermatitis enteropathica who showed significant recovery from severe symptoms after receiving a therapeutic zinc supplement.

In this study, oral etretinate resulted in increased hair length and loss of beading in a childhood monilethrix case, while the scalp's keratosis pilaris persisted.

In this study on mice, a hydro-alcoholic solution containing kopexil significantly enhanced hair growth and increased hair-promoting factors without causing notable liver or kidney toxicity compared to minoxidil.

This study observed that conjugates of the anticancer drug raltitrexed with dextran and albumin were more cytotoxic than the free drug at high concentrations, altering cell cycle effects.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

Hyaluronic acid microneedles help deliver minoxidil derivatives effectively for hair regrowth.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This report highlights a case of a 35-year-old man developing alopecia universalis following alemtuzumab treatment for multiple sclerosis, suggesting potential links between this medication and drug-induced alopecia areata, though the genetic overlap of the conditions may also play a role.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

This study found that allergen treatment in alopecia areata mice appeared to alter leukocyte subset distribution and impaired dendritic cell migration, which may affect T-cell activation and hair follicle recovery.

This article reviews current treatments for alopecia areata, discussing the potential role of JAK inhibitors and noting the need for further clinical trials, but it reports no new results.